Clinicopathological and prognostic role of CEP55 expression in cancer patients: A meta-analysis of 31 studies with 12,543 patients

iLABMED Pub Date : 2024-08-19 DOI:10.1002/ila2.50

Jiangguo Zhang, Xiaoyin Zhang

{"title":"Clinicopathological and prognostic role of CEP55 expression in cancer patients: A meta-analysis of 31 studies with 12,543 patients","authors":"Jiangguo Zhang, Xiaoyin Zhang","doi":"10.1002/ila2.50","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Dysregulated expression of centrosomal protein 55 (CEP55) has been detected in multiple types of cancers. However, the clinical value of CEP55 expression in cancer is controversial. The current meta-analysis quantitatively investigated the association between CEP55 expression and prognostic outcomes in cancers.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A literature search was performed using the Chinese National Knowledge Infrastructure (CNKI), Wanfang databases, Web of Science, Embase, MEDLINE, PubMed, and Cochrane Library for primary studies. The pooled hazard ratios (HRs) and odds ratios (ORs) were used to investigate the association between CEP55 expression and its prognostic and clinicopathological value in cancers.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 12,543 patients from 31 studies were included in this meta-analysis. High CEP55 expression was significantly associated with poor differentiation, deeper tumor invasion and increased lymph node metastasis in cancer patients. The pooled results indicated that elevated CEP55 expression can predict a poor overall survival (OS) and disease-free survival (DFS) in cancers. These results should be interpreted with caution because of publication bias. However, the pooled HR for OS of lung cancers was 1.50 (95% <i>CI</i> = 1.36–1.67, <i>p</i> < 0.01) with no heterogeneity and publication bias.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>CEP55 overexpression correlated with poor cancer differentiation, deeper tumor invasion, and increased lymph node metastasis, suggesting that CEP55 may serve as a predictive and prognostic biomarker for cancers, especially for lung cancers.</p>\n </section>\n </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 4","pages":"327-340"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.50","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iLABMED","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ila2.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Dysregulated expression of centrosomal protein 55 (CEP55) has been detected in multiple types of cancers. However, the clinical value of CEP55 expression in cancer is controversial. The current meta-analysis quantitatively investigated the association between CEP55 expression and prognostic outcomes in cancers.

Methods

A literature search was performed using the Chinese National Knowledge Infrastructure (CNKI), Wanfang databases, Web of Science, Embase, MEDLINE, PubMed, and Cochrane Library for primary studies. The pooled hazard ratios (HRs) and odds ratios (ORs) were used to investigate the association between CEP55 expression and its prognostic and clinicopathological value in cancers.

Results

A total of 12,543 patients from 31 studies were included in this meta-analysis. High CEP55 expression was significantly associated with poor differentiation, deeper tumor invasion and increased lymph node metastasis in cancer patients. The pooled results indicated that elevated CEP55 expression can predict a poor overall survival (OS) and disease-free survival (DFS) in cancers. These results should be interpreted with caution because of publication bias. However, the pooled HR for OS of lung cancers was 1.50 (95% CI = 1.36–1.67, p < 0.01) with no heterogeneity and publication bias.

Conclusions

CEP55 overexpression correlated with poor cancer differentiation, deeper tumor invasion, and increased lymph node metastasis, suggesting that CEP55 may serve as a predictive and prognostic biomarker for cancers, especially for lung cancers.

Abstract Image

查看原文本刊更多论文

CEP55表达在癌症患者中的临床病理和预后作用：对31项研究12,543例患者的荟萃分析

中心体蛋白55 （CEP55）表达异常已在多种类型的癌症中被检测到。然而，CEP55在癌症中表达的临床价值存在争议。目前的荟萃分析定量研究了CEP55表达与癌症预后结果之间的关系。方法采用中国知网（CNKI）、万方数据库、Web of Science、Embase、MEDLINE、PubMed、Cochrane Library进行文献检索，进行初步研究。采用合并风险比（hr）和优势比（ORs）研究CEP55表达与肿瘤预后和临床病理价值之间的关系。结果来自31项研究的12,543例患者被纳入本荟萃分析。CEP55高表达与肿瘤患者分化差、肿瘤侵袭更深、淋巴结转移增加显著相关。综合结果表明，CEP55表达升高可以预测癌症患者较差的总生存期（OS）和无病生存期（DFS）。由于存在发表偏倚，这些结果应谨慎解读。然而，肺癌OS的总HR为1.50 (95% CI = 1.36-1.67, p <；0.01)，无异质性和发表偏倚。结论CEP55过表达与肿瘤分化差、肿瘤侵袭更深、淋巴结转移增加相关，提示CEP55可能是癌症，特别是肺癌的预测和预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

iLABMED

自引率

0.00%

发文量